Evotec SE Conference Call Transcript
Good morning, good afternoon. Welcome to Evotec. Today is an important day because it's a significant impact that will happen through the new partnership between Sandoz and Just-Evotec Biologics for the world. Why do I say this? Because when we think about access, then this partnership will make a huge contribution in the future. We have uploaded a presentation for this call that I will host together with Matthias Evers, who was pivotal to make this deal happen. When it comes to the presentation, I would like to guide you to Page #2, which gives you an overview of the tech partnership for biosimilars that we have initiated together with Sandoz.
Before that, let me start by a general definition of what a biosimilar is. The FDA defines a biosimilar is a biological product that is highly similar and has no clinically meaningful differences from an existing FDA-approved reference product. And these are differences when it comes to safety, purity and potency. That's a biosimilar. And I make this definition because typically
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |